Wyeth accused of 'branducating'

Share this article:

Pfizer paid about $55 million to resolve allegations that Wyeth, which it bought in 2009, used CME and other tactics to promote ulcer drug Protonix for off-label use in 2000 and 2001, the Justice Department said.

The complaint said Wyeth provided ostensibly unrestricted grants to CME providers, but the Protonix brand team “influenced virtually every aspect of these CME programs.”

Wyeth, the government alleged, even insisted that the CME program materials use the same color and appearance as Protonix promotional materials—“a tactic that Wyeth and the vendor called ‘branducation.'”

Pfizer denies the allegations.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?